Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 2/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | LIG1 | P18858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1780602 | 0.91 | MAPT (0.63) | MAP1LC3BGAAMAPTKDM1AALPL | |
| Formic Acid Methyl Ester SCHEMBL28834584 | 0.85 | MAP1LC3B (0.50) | MAP1LC3BGAAMAPTKDM1AALPL | |
| SCHEMBL717834 | 0.83 | ESR2 (0.50) | MAP1LC3BGAAMAPTKDM1AALPL | |
| SCHEMBL14492200 | 0.80 | GSK3B (0.53) | MAP1LC3BGAAMAPTALPLL3MBTL1 | |
| SCHEMBL658679 | 0.80 | MAP1LC3B (0.49) | MAP1LC3BALPLL3MBTL1TDP1ATM | |
| SCHEMBL715319 | 0.80 | ESR2 (0.50) | MAP1LC3BGAAMAPTALPLL3MBTL1 | |
| SCHEMBL18980759 | 0.80 | ESR2 (0.50) | MAP1LC3BGAAMAPTALPLL3MBTL1 | |
| SCHEMBL745535 | 0.77 | ESR2 (0.64) | MAP1LC3BKDM1AALPLTDP1LIG1 | |
| SCHEMBL10672428 | 0.77 | MAPT (0.77) | MAP1LC3BGAAMAPTTDP1SMN1; SMN2 | |
| SCHEMBL4138165 | 0.77 | MAP1LC3B (0.50) | MAP1LC3BALPLL3MBTL1TDP1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3555055-B1 | HYDROXY ISOXAZOLE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME LLC (US) | 2022-08-03 | — | — | EP | disclosed |
| US-10864211-B2 | Hydroxy isoxazole compounds useful as GPR120 agonists | MERCK SHARP & DOHME CORP. (US) | 2020-12-15 | — | — | US | disclosed |
| WO-2019244066-A2 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2019-12-26 | — | — | WO | disclosed |
| EP-3555055-A1 | HYDROXY ISOXAZOLE COMPOUNDS USEFUL AS GPR120 AGONISTS | Merck Sharp & Dohme Corp. (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20190269679-A1 | HYDROXY ISOXAZOLE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2019-09-05 | — | — | US | disclosed |
| WO-2018111734-A1 | HYDROXY ISOXAZOLE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-06-21 | — | — | WO | disclosed |
| EP-2881384-B1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO LTD (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-9738642-B2 | Triazolopyridine ether derivatives and their use in neurological and pyschiatric disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-9422240-B2 | Partially saturated nitrogen-containing heterocyclic compound | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-08-23 | — | — | US | disclosed |
| US-20160237081-A1 | TRIAZOLOPYRIDINE ETHER DERIVATIVES AND THEIR USE IN NEUROLOGICAL AND PYSCHIATRIC DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-18 | — | — | US | disclosed |
| EP-2881384-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Taisho Pharmaceutical Co., Ltd. (JP) | 2015-06-10 | — | — | EP | disclosed |
| WO-2015042243-A1 | TRIAZOLOPYRIDINE ETHER DERIVATIVES AND THEIR USE IN NEUROLOGICAL AND PYSCHIATRIC DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-26 | — | — | WO | disclosed |
| EP-2481735-A1 | Substituted heterocyclic derivatives and compositions and their pharmaceutical use as antibacterials | Pfizer Inc. (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20120065188-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC | 2012-03-15 | — | — | US | disclosed |
| US-20120065188-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC | 2012-03-15 | — | — | US | disclosed |
| US-20110092480-A1 | Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions | PFIZER INC. | 2011-04-21 | — | — | US | disclosed |
| US-20110092480-A1 | Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions | PFIZER INC. | 2011-04-21 | — | — | US | disclosed |
| WO-2008139288-A2 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND COMPOSITIONS AND THEIR PHARMACEUTICAL USE AS ANTIBACTERIALS | PFIZER INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| US-20080280879-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC | 2008-11-13 | — | — | US | disclosed |
| US-20080280879-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10864211-B2 | Hydroxy isoxazole compounds useful as GPR120 agonists | GPR119, GPR88, GPR180 | MAP1LC3B 2088/4885GAA 1311/4885MAPT 4490/4885 |
| US-20160237081-A1 | TRIAZOLOPYRIDINE ETHER DERIVATIVES AND THEIR USE IN NEUROLOGICAL AND PYSCHIATRIC DISORDERS | GRM2, GRIK2, GRIA2 | MAP1LC3B 1049/4885GAA 1865/4885MAPT 396/4885 |
| US-20120065188-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | XDH, CYP2D6, F12 | MAP1LC3B 4835/4885GAA 2370/4885MAPT 4323/4885 |
| US-20190269679-A1 | HYDROXY ISOXAZOLE COMPOUNDS USEFUL AS GPR120 AGONISTS | GPR119, GPR88, GPR180 | MAP1LC3B 2088/4885GAA 1311/4885MAPT 4490/4885 |
| US-20080280879-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | XDH, CYP2D6, F12 | MAP1LC3B 4835/4885GAA 2370/4885MAPT 4323/4885 |
| US-20110092480-A1 | Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions | XDH, CYP2D6, F12 | MAP1LC3B 4835/4885GAA 2370/4885MAPT 4323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.